Literature DB >> 28702753

Magnifying NBI Patterns of Gastric Mucosa After Helicobacter pylori Eradication and Its Potential Link to the Gastric Cancer Risk.

Tomomitsu Tahara1, Sayumi Tahara2, Tetsuya Tuskamoto2, Noriyuki Horiguchi3, Dai Yoshida3, Tomohiko Kawamura3, Masaaki Okubo3, Mitsuo Nagasaka3, Yoshihito Nakagawa3, Makoto Urano2, Makoto Kuroda2, Tomoyuki Shibata3, Naoki Ohmiya3.   

Abstract

BACKGROUND: Gastric cancer develops after successful H. pylori eradication in patients with severe atrophic gastritis. We classified atrophic and non-atrophic mucosa of gastric body using magnifying NBI endoscopy in patients after successful H. pylori eradication.
MATERIALS AND METHODS: One hundred and twenty-five patients after successful H. pylori eradication (median period after eradication: 36 months) were enrolled. Magnifying NBI patterns in the uninvolved gastric body were divided into the following: restored-small, round pits, accompanied with honeycomb-like subepithelial capillary networks; atrophic-well-demarcated oval or tubulovillous pits with clearly visible coiled or wavy vessels. The subjects were also classified into the three types: Grade 0-restored pattern is shown in all or almost the entire area of gastric body; Grade 1-mixture of restored and atrophic pattern, there is a considerable portion of the atrophic area in the lesser curvature; Grade 2-atrophic pattern is shown in all or almost the entire area of the gastric body.
RESULTS: Sensitivity and specificity for atrophic type for detection of histological intestinal metaplasia were 95.9 and 98.3%, respectively. No association was observed between the prevalence of Grades 0, 1 and 2 and duration after eradication, while grades 1 and 2 were significantly frequent in gastric cancer patients diagnosed both before (27/35: 77%) and after (23/31: 74%) eradication, compared to the cancer-free subjects (15/59: 25%) (P < 0.001). The grades 1 and 2 were also common in patients who underwent H. pylori eradication for gastric ulcer.
CONCLUSIONS: Magnifying the NBI pattern well correlates with pathological status of gastric mucosa after H. pylori eradication and may predict gastric cancer occurrence.

Entities:  

Keywords:  Gastric atrophy; Gastric cancer; H. pylori eradication; Magnifying NBI endoscopy

Mesh:

Year:  2017        PMID: 28702753     DOI: 10.1007/s10620-017-4676-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Autofluorescence imaging for predicting development of metachronous gastric cancer after Helicobacter pylori eradication.

Authors:  Noboru Hanaoka; Noriya Uedo; Akiko Shiotani; Takuya Inoue; Yoji Takeuchi; Koji Higashino; Ryu Ishihara; Hiroyasu Iishi; Ken Haruma; Masaharu Tatsuta
Journal:  J Gastroenterol Hepatol       Date:  2010-12       Impact factor: 4.029

2.  Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils.

Authors:  N Shimizu; Y Ikehara; K Inada; H Nakanishi; T Tsukamoto; K Nozaki; M Kaminishi; S Kuramoto; A Sugiyama; T Katsuyama; M Tatematsu
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

3.  Helicobacter pylori infection and the development of gastric cancer.

Authors:  N Uemura; S Okamoto; S Yamamoto; N Matsumura; S Yamaguchi; M Yamakido; K Taniyama; N Sasaki; R J Schlemper
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

4.  Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer.

Authors:  Yasumasa Ezoe; Manabu Muto; Noriya Uedo; Hisashi Doyama; Kenshi Yao; Ichiro Oda; Kazuhiro Kaneko; Yoshiro Kawahara; Chizu Yokoi; Yasushi Sugiura; Hideki Ishikawa; Yoji Takeuchi; Yoshibumi Kaneko; Yutaka Saito
Journal:  Gastroenterology       Date:  2011-08-19       Impact factor: 22.682

5.  Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori.

Authors:  Keiko Yamamoto; Mototsugu Kato; Masakazu Takahashi; Masahira Haneda; Keisuke Shinada; Urara Nishida; Takeshi Yoshida; Norikazu Sonoda; Shoko Ono; Manabu Nakagawa; Yasuaki Mori; Soichi Nakagawa; Katsuhiro Mabe; Yuichi Shimizu; Jun Moriya; Kanako Kubota; Yoshihiro Matsuno; Tadakazu Shimoda; Hidenobu Watanabe; Masahiro Asaka
Journal:  Helicobacter       Date:  2011-06       Impact factor: 5.753

6.  Narrow-band imaging in the diagnosis of colorectal mucosal lesions: a pilot study.

Authors:  H Machida; Y Sano; Y Hamamoto; M Muto; T Kozu; H Tajiri; S Yoshida
Journal:  Endoscopy       Date:  2004-12       Impact factor: 10.093

7.  Helicobacter pylori infection induces gastric cancer in mongolian gerbils.

Authors:  T Watanabe; M Tada; H Nagai; S Sasaki; M Nakao
Journal:  Gastroenterology       Date:  1998-09       Impact factor: 22.682

8.  Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.

Authors:  Kazutoshi Fukase; Mototsugu Kato; Shogo Kikuchi; Kazuhiko Inoue; Naomi Uemura; Shiro Okamoto; Shuichi Terao; Kenji Amagai; Shunji Hayashi; Masahiro Asaka
Journal:  Lancet       Date:  2008-08-02       Impact factor: 79.321

Review 9.  Helicobacter pylori and gastric carcinogenesis.

Authors:  P Correa
Journal:  Am J Surg Pathol       Date:  1995       Impact factor: 6.394

10.  Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data.

Authors:  P Sipponen; M Kekki; J Haapakoski; T Ihamäki; M Siurala
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

View more
  2 in total

Review 1.  Characteristics and Early Diagnosis of Gastric Cancer Discovered after Helicobacter pylori Eradication.

Authors:  Masanori Ito; Shinji Tanaka; Kazuaki Chayama
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

Review 2.  What Is New in Helicobacter pylori Diagnosis. An Overview.

Authors:  Maria Pina Dore; Giovanni Mario Pes
Journal:  J Clin Med       Date:  2021-05-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.